Combining a new immune therapy with radiation for head and neck cancer
Official title: Combination of CB101 and radiation therapy in head and neck squamous cell carcinoma
Funded at Curebiotech, INC. · NIH-10545347 · Data updated 2026-11-12
This study is looking at a new treatment called CB101, which is given directly into tumors along with radiation therapy, to help improve outcomes for patients with advanced head and neck cancer who have few good options left.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Curebiotech, INC. NIH-funded |
| Lab location | 1 site (Philadelphia, UNITED STATES) |
| Project start | September 1, 2022 |
| Project end | August 31, 2025 |
| Funding year | 2022 |
| Award (this year) | $250,876 |
| NIH project number | 1R41CA268252-01A1 |
| Project ID | NIH-10545347 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with locoregionally advanced or relapsed head and neck squamous cell carcinoma who have not responded well to standard treatments.
✕Less likely to help
Patients with early-stage head and neck cancer or those who have not yet undergone any treatment may not benefit from this research.
What this research studies
This research investigates the use of a novel immune therapy called CB101 in combination with radiation therapy for patients suffering from head and neck squamous cell carcinoma (HNSCC). The approach involves delivering CB101 directly into tumors to enhance the immune response while minimizing systemic side effects. The study aims to improve treatment outcomes for patients with advanced or relapsed HNSCC, which currently has limited effective treatment options. By utilizing a controlled release formulation of CB101, the research seeks to provide a more effective and localized treatment strategy.
Why it matters
Potential benefit: If successful, this research could significantly improve survival rates and quality of life for patients with advanced head and neck cancer.
How similar studies have gone: While immunotherapy approaches have been explored, the specific combination of CB101 with radiation therapy represents a novel strategy that has shown promising results in preclinical models.
Where this research is happening
-
Curebiotech, INC.
Philadelphia, United States Active
Researchers
- Principal investigator: Schure, Louis I — Curebiotech, INC.
- Study coordinator: Schure, Louis I
Related research
Other NIH-funded projects on the same topics.
-
Blocking NRF2 to help radiation work better for head and neck cancer
Trying drugs that block a protein called NRF2 to help radiation therapy work better for people with head and neck squamous cell carcinoma.
-
Improving radiation therapy for head and neck cancer by targeting NRF2
This study is looking at how blocking a protein called NRF2 might help make radiation therapy work better for people with head and neck cancer, so they can have a better chance at treatment success.
-
Novel idea: Epstein-Barr virus and eye cancer in people living with HIV in Zimbabwe
A study explores whether Epstein-Barr virus could cause a type of eye cancer in people living with HIV in Zimbabwe.
-
Oral cancer recurrence predictor using tumor microbes and gene activity
This NIH grant explores how bacteria and immune signals inside oral cancer tumors relate to whether the cancer comes back, with the aim of making a practical risk predictor for patients.
-
Data-driven classification of aggressive tissue traits to predict cancer outcomes in HPV-negative head and neck cancer
A clinician-science grant uses data science and AI to identify tissue patterns in HPV-negative head and neck cancer that may predict how long patients stay cancer-free.
-
Targeting PIPKIγi5 to boost immune responses against head and neck cancer
A study to see if blocking a specific enzyme, PIPKIγi5, can make head and neck cancer more visible to the immune system and more responsive to existing immunotherapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.